Chief Executive Officer, QUEoncologyHealthier menopause treatments
| Role | Organisation | Sources |
|---|---|---|
| Chief Executive Officer | QUEoncologyHealthier menopause treatments | Brandon BioCatalyst portfolio (Thu 1 Aug 2019), Brandon BioCatalyst portfolio (Tue 2 Apr 2019) |
| Chief Executive Officer | Que Oncology | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming Dr Rob Crombie. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
QUE Oncology expands its Phase II trial of Q-122, a therapy for hot flushes in breast cancer patients on endocrine therapy, to New Zealand sites, with trials also running in Australia and the United States.
Biotech company QUE Oncology adds two experienced pharmaceutical executives, Julie Cherrington and Elizabeth Cermak, to its board as it develops a non-hormonal breast cancer therapy.
Clinical-stage biotech QUE Oncology adds two experienced life science executives, Julie Cherrington and Elizabeth Cermak, to its board, while continuing trials of its non-hormonal therapy for breast cancer hot flashes.
QUE Oncology is beginning placebo-controlled Phase II trials of its drug Q-122 at US hospitals, testing it against hot flashes in breast cancer patients on endocrine therapy, with its CEO and a lead investigator quoted.